Moxetumomab pasudotox
RxNorm 2099295

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2099295 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: moxetumomab pasudotox.

The following semantic concepts and normalized strings are associated with this clinical entity:

IN
Moxetumomab pasudotox
AUI:10768134
PT
Moxetumomab pasudotox
AUI:10807491
FN
Moxetumomab pasudotox (substance)
AUI:10807492
PT
Moxetumomab pasudotox-containing product
AUI:10807495
FN
Product containing moxetumomab pasudotox (medicinal product)
AUI:10811819

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

INPrescribable

Ingredient (IN):
Moxetumomab pasudotox
(Atom ID: 10768134)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
moxetumomab pasudotox
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2099295
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
10768134
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
IN
Ingredient (A compound or moiety that gives the drug its distinctive clinical properties. Ingredients generally use the United States Adopted Name (USAN).)
Source Code
2099295
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
UNII Crosswalk
2NDX4B6N8F - MOXETUMOMAB PASUDOTOX (INGREDIENT SUBSTANCE)
RxNorm to Unique Ingredient Identifier crosswalk.

PTPrescribable

Designated preferred name (PT):
Moxetumomab pasudotox
(Atom ID: 10807491)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Moxetumomab pasudotox
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2099295
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
10807491
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PT
Designated preferred name ()
Source Code
781124007
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
US Edition of SNOMED CT (SNOMEDCT_US)
The official name and abbreviation for the vocabulary source.
Source Version
2026_01_31
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
National Library Of Medicine, NLM is a Charter Member of SNOMED International on behalf of the U.S., National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, 1-888-FIND-NLM (1-888-346-3656), , https://support.nlm.nih.gov/support/create-case/,
Source licensing contact information.
UNII Crosswalk
2NDX4B6N8F - MOXETUMOMAB PASUDOTOX (INGREDIENT SUBSTANCE)
RxNorm to Unique Ingredient Identifier crosswalk.

FNPrescribable

Full form of descriptor (FN):
Moxetumomab pasudotox (substance)
(Atom ID: 10807492)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Moxetumomab pasudotox (substance)
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2099295
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
10807492
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
FN
Full form of descriptor ()
Source Code
781124007
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
US Edition of SNOMED CT (SNOMEDCT_US)
The official name and abbreviation for the vocabulary source.
Source Version
2026_01_31
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
National Library Of Medicine, NLM is a Charter Member of SNOMED International on behalf of the U.S., National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, 1-888-FIND-NLM (1-888-346-3656), , https://support.nlm.nih.gov/support/create-case/,
Source licensing contact information.
UNII Crosswalk
2NDX4B6N8F - MOXETUMOMAB PASUDOTOX (INGREDIENT SUBSTANCE)
RxNorm to Unique Ingredient Identifier crosswalk.

PTPrescribable

Designated preferred name (PT):
Moxetumomab pasudotox-containing product
(Atom ID: 10807495)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Moxetumomab pasudotox-containing product
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2099295
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
10807495
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PT
Designated preferred name ()
Source Code
781155001
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
US Edition of SNOMED CT (SNOMEDCT_US)
The official name and abbreviation for the vocabulary source.
Source Version
2026_01_31
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
National Library Of Medicine, NLM is a Charter Member of SNOMED International on behalf of the U.S., National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, 1-888-FIND-NLM (1-888-346-3656), , https://support.nlm.nih.gov/support/create-case/,
Source licensing contact information.
UNII Crosswalk
2NDX4B6N8F - MOXETUMOMAB PASUDOTOX (INGREDIENT SUBSTANCE)
RxNorm to Unique Ingredient Identifier crosswalk.

FNPrescribable

Full form of descriptor (FN):
Product containing moxetumomab pasudotox (medicinal product)
(Atom ID: 10811819)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Product containing moxetumomab pasudotox (medicinal product)
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2099295
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
10811819
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
FN
Full form of descriptor ()
Source Code
781155001
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
US Edition of SNOMED CT (SNOMEDCT_US)
The official name and abbreviation for the vocabulary source.
Source Version
2026_01_31
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
National Library Of Medicine, NLM is a Charter Member of SNOMED International on behalf of the U.S., National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, 1-888-FIND-NLM (1-888-346-3656), , https://support.nlm.nih.gov/support/create-case/,
Source licensing contact information.
UNII Crosswalk
2NDX4B6N8F - MOXETUMOMAB PASUDOTOX (INGREDIENT SUBSTANCE)
RxNorm to Unique Ingredient Identifier crosswalk.

Patient Education

Moxetumomab Pasudotox-tdfk Injection


Moxetumomab pasudotox-tdfk injection is used to treat hairy cell leukemia (cancer of a certain type of white blood cell) that has returned or has not responded after at least two other cancer treatments. Moxetumomab pasudotox-tdfk injection is in a class of medications called monoclonal antibodies. It works by helping your immune system to slow or stop the growth of cancer cells.
[Learn More]


Cancer Chemotherapy


Normally, your cells grow and die in a controlled way. Cancer cells keep growing without control. Chemotherapy is drug therapy for cancer. It works by killing the cancer cells, stopping them from spreading, or slowing their growth. However, it can also harm healthy cells, which causes side effects.

You may have a lot of side effects, some, or none at all. It depends on the type and amount of chemotherapy you get and how your body reacts. Some common side effects are fatigue, nausea, vomiting, pain, and hair loss. There are ways to prevent or control some side effects. Talk with your health care provider about how to manage them. Healthy cells usually recover after chemotherapy is over, so most side effects gradually go away.

Your treatment plan will depend on the cancer type, the chemotherapy drugs used, the treatment goal, and how your body responds. Chemotherapy may be given alone or with other treatments. You may get treatment every day, every week, or every month. You may have breaks between treatments so that your body has a chance to build new healthy cells. You might take the drugs by mouth, in a shot, as a cream, or intravenously (by IV).

NIH: National Cancer Institute


[Learn More]


* Please review the disclaimer below.